Calendar

Nov
4
Wed
Targeting Therapy in Acute Myeloid Leukemia (AML): Improving the Management of Treatment-Naïve Patients in the Department of Veterans Affairs
Nov 4 2020 @ 12:00 am – Nov 4 2021 @ 11:45 pm

Targeting Therapy in Acute Myeloid Leukemia (AML): Improving the Management of Treatment-Naïve Patients in the Department of Veterans Affairs

View Activity

 

PROGRAM CHAIR & FACULTY PRESENTER

Michael R. Grunwald, MD
Chief, Leukemia Division
Associate Professor, Atrium Health
Department of Hematologic Oncology and Blood Disorders
Levine Cancer Institute
Charlotte, NC

PROGRAM OVERVIEW

This activity will cover the management of patients with treatment-naïve AML.

EDUCATIONAL AUDIENCE

This educational activity is intended for US-based hematologists, medical oncologists, and other healthcare providers involved in the management of treatment-naïve AML.

LEARNING OBJECTIVES

Upon completion of the program, attendees should be able to:

  • Explain how common mutations and abnormalities in patients with previously untreated AML affect treatment decision-making and management strategies
  • Evaluate the efficacy and safety of available and emerging therapeutic approaches for patients with previously untreated AML
  • Incorporate diagnostic and evidence-based therapeutic strategies for patients with previously untreated AML
  • Discuss the benefits of effective communication between health care providers and patients with previously untreated AML

ACCREDITATION STATEMENT

Med Learning Group is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

This CME activity was planned and produced in accordance with the ACCME Essentials.

CREDIT DESIGNATION STATEMENT

Med Learning Group designates this enduring activity for a maximum of 1.0 AMA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the enduring activity.

NURSING CREDIT INFORMATION

Purpose: This program would be beneficial for nurses involved in the treatment of patients with AML.

CNE Credits: 1.0 ANCC Contact Hour

CNE ACCREDITATION STATEMENT

Ultimate Medical Academy/Complete Conference Management (CCM) is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s Commission on Accreditation.

Awarded 1.0 contact hour of continuing nursing education of RNs and APNs.

DISCLOSURE POLICY STATEMENT

In accordance with the Accreditation Council for Continuing Medical Education (ACCME) Standards for Commercial Support, educational programs sponsored by Med Learning Group must demonstrate balance, independence, objectivity, and scientific rigor. All faculty, authors, editors, staff, and planning committee members participating in an MLG-sponsored activity are required to disclose any relevant financial interest or other relationship with the manufacturer(s) of any commercial product(s) and/or provider(s) of commercial services that are discussed in an educational activity.

DISCLOSURE OF CONFLICTS OF INTEREST

Dr. Michael Grunwald has received consultant fees from Incyte, BMS/Celgene, Pfizer, Cardinal Health, Amgen, Merck, Agios, AbbVie, Daiichi Sankyo, Trovagene, Astellas, and Premier, and received fees for non-CME services from Incyte. He has been contracted for research for Amgen, Incyte, Genentech/Roche, Janssen, Forma Therapeutics, and Novartis. He has ownership interest in Medtronic.

CME Content Review
The content of this activity was independently peer reviewed.
The reviewer of this activity has nothing to disclose.

CNE Content Review
The content of this activity was independently peer reviewed.
The reviewer of this activity has nothing to disclose.

The staff, planners, and managers reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME/CE activity:

Matthew Frese, General Manager of Med Learning Group has nothing to disclose.
Christina Gallo, SVP Educational Development for Med Learning Group has nothing to disclose.
Marcello A. Morgan, MD, MPH, Medical and Scientific Services for Med Learning Group has nothing to disclose.
Lauren Welch, MA, VP of Accreditation and Outcomes for Med Learning Group has nothing to disclose.
Russie Allen, Accreditation and Outcomes Coordinator has nothing to disclose.
Jessica McMullen, MPH, Program Manager for Med Learning Group has nothing to disclose.

DISCLOSURE OF UNLABELED USE

Med Learning Group requires that faculty participating in any CME activity disclose to the audience when discussing any unlabeled or investigational use of any commercial product or device not yet approved for use in the United States.

During the course of this lecture, the faculty may mention the use of medications for both FDA-approved and non-approved indications

METHOD OF PARTICIPATION

There are no fees for participating and receiving CME credit for this enduring activity. To receive CME/CNE credit participants must:

  1. Read the CME/CNE information and faculty disclosures.
  2. Participate in the enduring activity.
  3. Complete the evaluation form.

You will receive your certificate as a downloadable file.

DISCLAIMER

Med Learning Group makes every effort to develop CME activities that are scientifically based. This activity is designed for educational purposes. Participants have a responsibility to utilize this information to enhance their professional development in an effort to improve patient outcomes. Conclusions drawn by the participants should be derived from careful consideration of all available scientific information. The participant should use his/her clinical judgment, knowledge, experience, and diagnostic decision-making before applying any information, whether provided here or by others, for any professional use.

For CME questions, please contact Med Learning Group at info@medlearninggroup.com.

Contact this CME provider at Med Learning Group for privacy and confidentiality policy statement information at www.medlearninggroup.com/privacy-policy/

AMERICANS WITH DISABILITIES ACT

Staff will be glad to assist you with any special needs. Please contact Med Learning Group prior to participating at info@medlearninggroup.com

 

View Activity

Copyright © 2020 Med Learning Group. All rights reserved. These materials may be used for personal use only.
Any rebroadcast, distribution, or reuse of this presentation or any part of it in any form for other than personal use without the express written permission of Med Learning Group is prohibited.

Sep
7
Tue
How Can You Use Targeted Therapies to Improve Clinical Decision-Making and Health Outcomes for Veterans with Acute Myeloid Leukemia?
Sep 7 2021 @ 12:00 am – Sep 7 2022 @ 3:20 am

How Can You Use Targeted Therapies to Improve Clinical Decision-Making and Health Outcomes for Veterans with Acute Myeloid Leukemia?

View Activity

PROGRAM CHAIR & FACULTY PRESENTER

Michael R. Grunwald, MD
Chief, Leukemia Division
Levine Cancer Institute, Atrium Health
Charlotte, NC

PROGRAM OVERVIEW

This activity will explore the management of patients with newly diagnosed, relapsed/refractory, and secondary acute myeloid leukemia (AML).

EDUCATIONAL AUDIENCE

This educational activity is intended for hematologists, community oncologists and clinicians involved in the assessment, monitoring, and treatment of AML in the Department of Veterans Affairs.

LEARNING OBJECTIVES

Upon completion of the program, attendees should be able to:

  • Evaluate how genetic and molecular markers aid in determining treatment strategies for patients with AML
  • Personalize therapy for the treatment of newly diagnosed, relapsed/refractory (R/R), and secondary AML based on disease‐ and patient‐specific factors and communicate these treatment plans using shared decision-making strategies in the inpatient and outpatient settings
  • Identify adverse events associated with AML treatment to appropriately prevent and/or manage these potential effects

ACCREDITATION STATEMENT

Med Learning Group is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

This CME activity was planned and produced in accordance with the ACCME Essentials.

CREDIT DESIGNATION STATEMENT

Med Learning Group designates this enduring activity for a maximum of 1.0 AMA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the enduring activity.

NURSING CREDIT INFORMATION

Purpose: This program would be beneficial for nurses involved in the care and treatment of patients with AML.
CNE Credits: 1.0 ANCC Contact Hour.

CNE ACCREDITATION STATEMENT

Ultimate Medical Academy/Complete Conference Management (CCM) is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s Commission on Accreditation. Awarded 1.0 contact hour of continuing nursing education of RNs and APNs.

DISCLOSURE POLICY STATEMENT

In accordance with the Accreditation Council for Continuing Medical Education (ACCME) Standards for Commercial Support, educational programs sponsored by Med Learning Group must demonstrate balance, independence, objectivity, and scientific rigor. All faculty, authors, editors, staff, and planning committee members participating in an MLG-sponsored activity are required to disclose any relevant financial interest or other relationship with the manufacturer(s) of any commercial product(s) and/or provider(s) of commercial services that are discussed in an educational activity.

DISCLOSURE OF CONFLICTS OF INTEREST

Michael R. Grunwald, MD, reports the following disclosures:

  • Consulting: AbbVie, Agios, Amgen, Astellas, Blueprint Medicines, Bristol Myers Squibb, Cardinal Health, Daiichi Sankyo, Gamida Cell, Gilead, Incyte, Invitae, Karius, Ono Pharmaceutical, Pfizer, Premier, Sierra Oncology, Stemline
  • Research funding (institution): Incyte, Janssen
  • Stock ownership: Medtronic

CME Content Review
The content of this activity was independently peer reviewed.
The reviewer of this activity has nothing to disclose.

CNE Content Review
The content of this activity was independently peer reviewed.
The reviewer of this activity has nothing to disclose.

Staff, Planners, and Managers
The staff, planners, and managers reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME/CE activity:
Matthew Frese, General Manager of Med Learning Group has nothing to disclose.
Christina Gallo, SVP Educational Development for Med Learning Group has nothing to disclose.
Jessica McMullen, MPH, Program Manager for Med Learning Group has nothing to disclose.
Diana Tommasi, PharmD, Medical Director for Med Learning Group has nothing to disclose.
Lauren Welch, MA, VP of Accreditation and Outcomes for Med Learning Group has nothing to disclose.
Russie Allen, Accreditation and Outcomes Coordinator for Med Learning Group has nothing to disclose.

DISCLOSURE OF UNLABELED USE

Med Learning Group requires that faculty participating in any CME activity disclose to the audience when discussing any unlabeled or investigational use of any commercial product or device not yet approved for use in the United States.

During the course of this lecture, the faculty may mention the use of medications for both FDA-approved and non-approved indications.

METHOD OF PARTICIPATION

There are no fees for participating and receiving CME credit for this enduring activity. To receive CME/CNE credit participants must:

  1. Read the CME/CNE information and faculty disclosures.
  2. Participate in the enduring activity.
  3. Complete the online evaluation form.

You will receive your certificate as a downloadable file.

DISCLAIMER

Med Learning Group makes every effort to develop CME activities that are scientifically based. This activity is designed for educational purposes. Participants have a responsibility to utilize this information to enhance their professional development in an effort to improve patient outcomes. Conclusions drawn by the participants should be derived from careful consideration of all available scientific information. The participant should use his/her clinical judgment, knowledge, experience, and diagnostic decision-making before applying any information, whether provided here or by others, for any professional use.

For CME questions, please contact Med Learning Group at info@medlearninggroup.com.

RELEASE DATE: September 7, 2021

EXPIRATION DATE: September 7, 2022

Contact this CME provider at Med Learning Group for privacy and confidentiality policy statement information at: www.medlearninggroup.com/privacy-policy/

AMERICANS WITH DISABILITIES ACT

Staff will be glad to assist you with any special needs. Please contact Med Learning Group prior to participating at info@medlearninggroup.com

Copyright © 2021 Med Learning Group. All rights reserved. These materials may be used for personal use only. Any rebroadcast, distribution, or reuse of this presentation or any part of it in any form for other than personal use without the express written permission of Med Learning Group is prohibited.

 

View Activity

 

Sep
29
Wed
How Can You Improve Your Approaches to Care for Veterans with Chronic Lymphocytic Leukemia? Insights from the Experts
Sep 29 2021 @ 8:00 am – Sep 29 2022 @ 9:00 am

How Can You Use Targeted Therapies to Improve Clinical Decision-Making and Health Outcomes for Veterans with Acute Myeloid Leukemia?

View Activity

 

PROGRAM CHAIR AND SPEAKING FACULTY
Ryan Jacobs, MD
Principal Investigator of CLL Clinical Trials
Department of Hematology, Lymphoma Division
Levine Cancer Institute/Atrium Health
Charlotte, NC

PROGRAM OVERVIEW
This activity will cover the assessment, monitoring, and treatment of chronic lymphocytic leukemia (CLL) in the Department of Veterans Affairs.

TARGET AUDIENCE
This educational activity is intended for community oncologists, hematologists, and clinicians involved in the assessment, monitoring, and treatment of CLL in the Department of Veterans Affairs.

LEARNING OBJECTIVES
On completing the program, attendees should be able to:
• Assess how genetic and molecular markers aid in determining treatment strategies for patients with CLL
• Evaluate the role of minimal residual disease (MRD) in monitoring the effectiveness of treatment approaches for CLL and its clinical implications
• Individualize selection of therapies for the treatment of treatment-naïve and relapsed/refractory (R/R) CLL based on disease‐ and patient‐specific factors and communicate these treatment plans using shared decision-making strategies
• Recognize adverse events associated with CLL treatment to appropriately prevent and/or manage these potential effects

ACCREDITATION STATEMENT
Med Learning Group is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

CREDIT DESIGNATION STATEMENT
Med Learning Group designates this enduring activity for a maximum of 1.0 AMA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the enduring activity.

NURSING CREDIT INFORMATION
Purpose: This program would be beneficial for nurses involved in the care of patients with CLL.
CNE Credits: 1.0 ANCC Contact Hour

CNE Accreditation Statement:
Ultimate Medical Academy/ Complete Conference Management (CCM) is accredited as a provider of continuing professional education development by the American Nurses Credentialing Center’s Commission on Accreditation.
Awarded 1.0 contact hour of continuing nursing education of RNs and APNs.

DISCLOSURE POLICY STATEMENT
In accordance with the Accreditation Council for Continuing Medical Education (ACCME) Standards for Commercial Support, educational programs sponsored by Med Learning Group must demonstrate balance, independence, objectivity, and scientific rigor. All faculty, authors, editors, staff, and planning committee members participating in an MLG-sponsored activity are required to disclose any relevant financial interest or other relationship with the manufacturer(s) of any commercial product(s) and/or provider(s) of commercial services that are discussed in an educational activity.

DISCLOSURE OF CONFLICTS OF INTEREST

Faculty Member Disclosure
Ryan Jacobs, MD Dr. Jacobs reports that he serves as a consultant for AstraZeneca, Secura Bio, Genentech, Adaptive, and TG Therapeutics. He also serves on speakers bureaus for Pharmacyclics, Janssen, AbbVie, TG Therapeutics, Secura Bio and AstraZeneca. Dr. Jacobs has also completed contracted research for Pharmacyclics, Teneobio, MEI Pharma, and TG Therapeutics.

 

CME Content Review
The content of this activity was independently peer reviewed.
The reviewer of this activity has nothing to disclose.

CNE Content Review
The content of this activity was peer reviewed by a nurse reviewer:
Douglas Cox, MSN, MHA, RN
Ultimate Medical Academy/CCM – Lead Nurse Planner

The reviewer of this activity has nothing to disclose.

Staff Planners and Managers
The staff, planners, and managers reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME/CE activity:
• Matthew Frese, MBA, General Manager of Med Learning Group, has nothing to disclose.
• Christina Gallo, SVP, Educational Development for Med Learning Group, has nothing to disclose.
• Marcello Morgan, MD, MPH, Medical and Scientific Services for Med Learning Group has nothing to disclose.
• Lauren Bartunek, Program Manager for Med Learning Group, has nothing to disclose.
• Lauren Welch, MA, VP, Accreditation and Outcomes for Med Learning Group, has nothing to disclose.
• Russie Allen, Accreditation and Outcomes Coordinator for Med Learning Group, has nothing to disclose.
• Douglas Cox, MSN, MHA, RN, UMA/CCM – LNP, has nothing to disclose.

DISCLOSURE OF UNLABELED USE
Med Learning Group requires that faculty participating in any CME activity disclose to the audience when discussing any unlabeled or investigational use of any commercial product or device not yet approved for use in the United States.
During the course of this lecture, the faculty may mention the use of medications for both FDA-approved and nonapproved indications.

METHOD OF PARTICIPATION
There are no fees for participating and receiving CME/CNE credit for this enduring activity. To receive CME/CNE credit participants must:
1. Read the CME/CNE information and faculty disclosures
2. Participate in the enduring activity
3. Complete posttest and evaluation form online.
You will receive your certificate as a downloadable file.

DISCLAIMER
Med Learning Group makes every effort to develop CME activities that are science-based.
This activity is designed for educational purposes. Participants have a responsibility to use this information to enhance their professional development in an effort to improve patient outcomes. Conclusions drawn by the participants should be derived from careful consideration of all available scientific information. The participant should use his/her clinical judgment, knowledge, experience, and diagnostic decision-making before applying any information, whether provided here or by others, for any professional use.

For CME questions, please contact Med Learning Group at info@medlearninggroup.com

RELEASE DATE: September 29, 2021

EXPIRATION DATE: September 29, 2022

Contact this CME provider at Med Learning Group for privacy and confidentiality policy statement information at http://medlearninggroup.com/privacy-policy/

Copyright © 2021 Med Learning Group. All rights reserved. These materials may be used for personal use only. Any rebroadcast, distribution, or reuse of this presentation or any part of it in any form for other than personal use without the express written permission of Med Learning Group is prohibited.

View Activity

Oct
6
Wed
CATALYST: Insights from the Experts to Navigate a Complex and Evolving Landscape in CLL and AML Management
Oct 6 @ 7:00 pm – 9:00 pm

CATALYST: Insights from the Experts to Navigate a Complex and Evolving Landscape in CLL and AML Management

Date: Wednesday, October 6, 2021
Time: 7:00 PM – 9:00 PM EST

To pre-register for the live event, please visit www.MLG-HM.com or call 1-207-847-0613

Oct
7
Thu
AML Grand Rounds @ Chicago, IL
Oct 7 @ 12:00 pm – 1:00 pm

Thursday, October 7, 2021
12:00-1:00pm

Location
Chicago, IL

Speaker
Hetty Carraway, MD, MBA

Oct
14
Thu
AML Grand Rounds
Oct 14 @ 12:00 pm – 1:00 pm

Thursday, October 14, 2021
12:00-1:00pm

Location
N/A

Speaker
Alice S. Mims, MD, MSCR

Oct
20
Wed
AML Grand Rounds @ Oxnard, CA
Oct 20 @ 12:15 pm – 1:15 pm

Wednesday, October 20, 2021
12:15-1:15pm

Location
Oxnard, CA

Speaker
David Rizzieri, MD

Oct
21
Thu
AML Grand Rounds @ Philadelphia, PA
Oct 21 @ 7:30 am – 8:30 am

Thursday, October 21, 2021
7:30-8:30am

Location
Philadelphia, PA

Speaker
Tapan M. Kadia, MD